{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:05:19Z","timestamp":1794863119273,"version":"4.9.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pyruvate kinase M2 (PKM2) is an enzyme that regulates the final process of glycolysis and exists in tetrameric and dimeric forms. The dimeric form of PKM2, also known as tumour M2-PK, increases when aerobic glycolysis is augmented, a feature observed in rheumatoid arthritis (RA). We investigated whether plasma tumour M2-PK is elevated in patients with RA and whether its levels correlate with disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Plasma levels of tumour M2-PK were measured for patients with RA (n=151), those with osteoarthritis (OA) (n=37), and controls (n=37). We evaluated the association between plasma tumour M2-PK and continuous variables using Pearson\u2019s correlation analysis, and multivariate logistic regression analysis to determine the association between plasma tumour M2-PK and disease activity status. Knee synovial tissue blocks from patients with RA and OA were subjected to real-time quantitative PCR (qPCR) using two different primers for PKM2 and tumour M2-PK immunohistochemical (IHC) staining.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The tumour M2-PK level significantly correlated with the disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) (r=0.546, p&amp;lt;0.001) and DAS28-C-reactive protein (CRP) (r=0.589, p&amp;lt;0.001). Moreover, repeat testing of tumour M2-PK levels in 20 patients revealed a significant decline in tumour M2-PK levels after reduction in inflammation (p&amp;lt;0.001). Area under the receiver operating characteristic curve (AUROC) analysis demonstrated that upon incorporation of tumour M2-PK, ESR, and CRP, the area under the curve was 0.962 for distinguishing moderate\/high from remission\/low disease activity. Adjusted logistic regression also revealed that a tumour M2-PK &amp;gt;43.9 U\/mL (OR 3.672, p=0.042) independently predicted moderate\/high disease activity status. Furthermore, tumour M2-PK levels in patients with RA were significantly higher than in those with OA and controls (all p&amp;lt;0.001). However, no differences were found in PKM2 expression in RA and OA synovial tissues as assessed by qPCR, and IHC analysis revealed negligible tumour M2-PK expression in the synovial tissues.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Circulating plasma tumour M2-PK levels may be a clinically useful indicator for evaluating disease activity and RA diagnosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.901555","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:03:05Z","timestamp":1660802585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of disease activity in patients with rheumatoid arthritis using plasma tumour M2-pyruvate kinase test"],"prefix":"10.3389","volume":"13","author":[{"given":"Sung Soo","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semcdb.2015.08.004","article-title":"Pyruvate kinase: Function, regulation and role in cancer","volume":"43","author":"Israelsen","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/abbs\/gms106","article-title":"Dual roles of PKM2 in cancer metabolism","volume":"45","author":"Wu","year":"2013","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13578-019-0317-8","article-title":"PKM2, function and expression and regulation","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.77","article-title":"Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy","volume":"16","author":"Hay","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00022","article-title":"Posttranslational modifications of pyruvate kinase M2: Tweaks that benefit cancer","volume":"8","author":"Prakasam","year":"2018","journal-title":"Front Oncol"},{"key":"B6","article-title":"Quantitative detection of tumor M2-PK in serum and plasma","volume":"19","author":"Hugo","year":"1999","journal-title":"Anticancer Res"},{"key":"B7","article-title":"Plasma tumor M2-pyruvate kinase levels in different cancer types","volume":"35","author":"Mu\u00f1oz-Colmenero","year":"2015","journal-title":"Anticancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"119694","DOI":"10.1016\/j.lfs.2021.119694","article-title":"Targeting pyruvate kinase muscle isoform 2 (PKM2) in cancer: What do we know so far","volume":"280","author":"Chhipa","year":"2021","journal-title":"Life Sci"},{"key":"B9","article-title":"The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer","volume":"20","author":"Schulze","year":"2000","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.8.5.579","article-title":"Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy","volume":"8","author":"Hardt","year":"2008","journal-title":"Expert Rev Mol Diagn"},{"key":"B11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12957-018-1360-3","article-title":"Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer","volume":"16","author":"Bandara","year":"2018","journal-title":"World J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(02)00720-6","article-title":"Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study","volume":"193","author":"Schneider","year":"2003","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(02)00404-4","article-title":"Tumor M2 pyruvate kinase\u2013determination in breast cancer patients receiving trastuzumab therapy","volume":"187","author":"Hoopmann","year":"2002","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00159","article-title":"Pyruvate kinase M2 and cancer: The role of PKM2 in promoting tumorigenesis","volume":"10","author":"Zahra","year":"2020","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01395","article-title":"Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes","volume":"10","author":"Yoshitomi","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01743","article-title":"Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis","volume":"10","author":"de Oliveira","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"107064","DOI":"10.1016\/j.intimp.2020.107064","article-title":"Role of glucose metabolism in aggressive phenotype of fibroblast-like synoviocytes: Latest evidence and therapeutic approaches in rheumatoid arthritis","volume":"89","author":"Masoumi","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.39608","article-title":"Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes","volume":"68","author":"Garcia-Carbonell","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American college of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on c-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13513","article-title":"2018 Update of the APLAR recommendations for treatment of rheumatoid arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20210706","article-title":"Human fibroblast-like synoviocyte isolation matter: a comparison between cell isolation from synovial tissue and synovial fluid from patients with rheumatoid arthritis","volume":"67","author":"Zafari","year":"2021","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107392","DOI":"10.1016\/j.intimp.2021.107392","article-title":"Fibroblast-like synoviocytes in rheumatoid arthritis: Surface markers and phenotypes","volume":"93","author":"Wu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2012.767","article-title":"Effects of the pro-inflammatory milieu on the dedifferentiation of cultured fibroblast-like synoviocytes","volume":"5","author":"Choi","year":"2012","journal-title":"Mol Med Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.34495","article-title":"Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14","volume":"64","author":"Nair","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2019.10.015","article-title":"Pharmacological activation of pyruvate kinase M2 inhibits CD4(+) T cell pathogenicity and suppresses autoimmunity","volume":"31","author":"Angiari","year":"2020","journal-title":"Cell Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/jdi.13478","article-title":"The PKM2 activator TEPP-46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF-1\u03b1 accumulation","volume":"12","author":"Liu","year":"2021","journal-title":"J Diabetes Investig"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160809","article-title":"Understanding the warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901021","article-title":"Upregulated PKM2 in macrophages exacerbates experimental arthritis via STAT1 signaling","volume":"205","author":"Xu","year":"2020","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13075-021-02437-7","article-title":"Increase of aerobic glycolysis mediated by activated T helper cells drives synovial fibroblasts towards an inflammatory phenotype: new targets for therapy","volume":"23","author":"Kvacskay","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02919","article-title":"PKM2: A potential regulator of rheumatoid arthritis via glycolytic and non-glycolytic pathways","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.molcel.2012.01.001","article-title":"Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase","volume":"45","author":"Gao","year":"2012","journal-title":"Mol Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27611","article-title":"Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer","volume":"119","author":"Dhar","year":"2013","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-015-9477-2","article-title":"The pathogenic role of angiogenesis in rheumatoid arthritis","volume":"18","author":"Elshabrawy","year":"2015","journal-title":"Angiogenesis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9481-x","article-title":"Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy","volume":"14","author":"Hathurusinghe","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S106508","article-title":"Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies","volume":"9","author":"Wu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1038\/s41598-022-07667-6","article-title":"Extracellular pyruvate kinase M2 promotes osteoclastogenesis and is associated with radiographic progression in early rheumatoid arthritis","volume":"12","author":"Han","year":"2022","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652771","article-title":"Metabolic control of autoimmunity and tissue inflammation in rheumatoid arthritis","volume":"12","author":"Qiu","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"19385","DOI":"10.1038\/s41598-021-98651-z","article-title":"TNF induces glycolytic shift in fibroblast like synoviocytes via GLUT1 and HIF1A","volume":"11","author":"Koedderitzsch","year":"2021","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"43165","DOI":"10.1038\/srep43165","article-title":"Resolution of TLR2-induced inflammation through manipulation of metabolic pathways in rheumatoid arthritis","volume":"7","author":"McGarry","year":"2017","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025270","article-title":"Synovial tissue inflammation in early and late osteoarthritis","volume":"64","author":"Benito","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/ar1003","article-title":"Are synovial biopsies of diagnostic value","volume":"5","author":"Bresnihan","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.704825","article-title":"Evidence that does not support pyruvate kinase M2 (PKM2)-catalyzed reaction as a rate-limiting step in cancer cell glycolysis","volume":"291","author":"Xie","year":"2016","journal-title":"J Biol Chem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.901555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:03:10Z","timestamp":1660802590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.901555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.901555"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.901555","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2022.901555.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2022.901555.s002","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"901555"}}